Abstract:Background Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma (RRMM), the optimal dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed to observe the efficacy and safety of different dose combinations of bortezomib and dexamethasone in the treatment of RRMM patients in China.Methods A total of 168 patients with relapsed multiple myeloma (MM) who were refractory to at lest two prior treatments were enrolled in this multicenter, open-label, non-randomized, prospective clinical trial. Twenty patients received 1.3 mg/m(2) of bortezomib twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles and oral or intravenous dexamethasone 20 mg on the day of and after each bortezomib dose (group 1); 66 patients received less than 1.3 mg/m(2) (0.7-1.0 mg/m(2)) of bortezomib and dexamethasone 20 mg on the same schedule (group 2); 37 patients received 1.3 mg/m(2) of bortezomib and dexamethasone 40 mg (group 3) and 45 patients received less than 1.3 mg/m(2) (0.7-1.0 mg/m(2)) of bortezomib and dexamethasone 40 mg (group 4). The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.Results The median age of groups 1 to 4 was 61, 62, 56, and 60 years, respectively. Most patients were in stages II/III of MM and the most common subtype was IgG. The rate of overall response to bortezomib and dexamethasone of group 1 to 4 was 72.2% (13/18), 73.8% (48/65), 78.8% (26/33) and 78.0% (32/41) (P=0.91), including a complete response rate of 22.2% (4/18), 20.0% (13/65), 33.3% (11/33) and 29.3% (12/41) (P=0.67), respectively. There was no statistical significance in time to progression and overall survival among these 4 groups (P>0.05). The most commonly adverse events of any grade in the entire 4 groups were fatigue, gastrointestinal effects, peripheral neuropathy and thrombocytopenia, and there was no significance in the number of adverse events among the 4 groups (P>0.05) except that peripheral neuropathy was reported more frequently in group 3 (36.3%) than in group 2 (13.8%, P<0.05) and group 4 (14.6%, P<0.05).Conclusions The combination of bortezomib and dexamethasone was associated with high responses in Chinese RRMM patients. No significant differences of efficacy were detected in different dose combinations of bortezomib and dexamethasone. Moreover, low dose of bortezomib reduced the incidence of peripheral neuropathy without affecting outcome in the treatment of patients with RRMM in China. Chin Med J 2011;124(19)2969-2974

Analysis of velcade combined with dexamethasone regimen treating multiple myeloma

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in Chinese Population.

Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

A Single-Center Retrospective Analysis of 100 Consecutive Cases Treated with Lenalidomide/bortezomib/dexamethasone in Newly Diagnosed Multiple Myeloma

Comparison of the efficacy and safety of standard and reduced doses of dexamethasone combined with bortezomib and adriamycin in the treatment of patients with multiple myeloma

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Clinical research of multiple myeloma with Velcade treatment

Efficacy of PAD regimen and VAD-like T regimen in the treatment of newly diagnosed multiple myeloma:a comparative study of 126 cases

Therapeutic Experience of Vincristine/cyclophosphamide/melphalan or Mitoxantrone/prednisone Combination Therapy Plus Thalidomide As First‐line Induction Therapy for Newly Diagnosed Multiple Myeloma in a Single Institution of China

Different Dose Combinations of Bortezomib and Dexamethasone in the Treatment of Relapsed or Refractory Myeloma: an Open-Label, Observational, Multi-Center Study in China.

Effect of bortizomib in combination with modified VAD chemotherapy on multiple myelo-ma

A Randomized Phase II, Open-Label and Multicenter Study of Combination Regimens of Bortezomib at Two Doses by Subcutaneous Injection for Newly Diagnosed Multiple Myeloma Patients

[Bortezomib-Based Combination Therapy for Newly Diagnosed Multiple Myeloma].

Bortezomib (velcade ™) Observational Study in China: Efficacy and Safety of Bortezomib-Based Regimen in 395 Relapsed or Refractory Multiple Myeloma Patients

Bortezomib Combined with Dexamethasone for Newly Diagnosed Multiple Myeloma

Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma]

Bortezomib in Combination with Dexamethasone and Subsequent Thalidomide for Newly-Diagnosed Multiple Myeloma: a Chinese Experience.

An open-label study of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the Chinese population

Effect of thalidomide in combination with modified VAD chemotherapy on multiple myeloma

Higher Single Dose of Bortezomib Plus Thalidomide and Dexamethasone is a Promising Therapy for Newly Diagnosed Multiple Myeloma